Clinical trials: TACE
Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of…
- Conditions
- Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02873442
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Adjuvant transarterial chemoembolization (TACE) is widely adopted in China for resectable hepatocellular carcinoma (HCC), yet its efficacy remains inconsistent.
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Adjuvant Therapy, Machine Learning
- Trial name
- HCC (NCT07562763)
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- Anhui Provincial Hospital
HCC, Quality of Life
Multidisciplinary Management of HCC in Elderly Patients
Aim of this study is to evaluate whether treating HCC recurrences in resected elderly patients is advantageous or not.
- Trial name
- NCT03875417
- Testing
- liver resection, Thermic ablation, Transcatheter arterial chemoembolization
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Policlinico Umberto I
Hepatocellular Carcinoma
Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
This study is a prospective non-randomized controlled study. The purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (TACE) for microvascular invasion (MVI) in…
- Trial name
- NCT02537158
- Testing
- Sorafenib, TACE
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma (HCC), Artificial Intelligent
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence…
- Conditions
- Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
- Trial name
- NCT07417800
- Testing
- AI adjuvant therapy
- Where
- China
- Volunteers
- 11,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Metastatic Breast Cancer
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
The purpose of this study is to evaluate the safety and tolerability of talectrectinib as treatment for Stage IV ILC with CDH1 mutation
- Trial name
- NCT06214793
- Testing
- Taletrectinib
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Megan Kruse, MD
Hepatocellular Carcinoma, HCC
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC).
- Trial name
- NCT04472767
- Testing
- Nivolumab, Ipilimumab, Cabozantinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Liver Cancer
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE) in patients with localized unresectable liver cancer.
- Trial name
- NCT00576199
- Testing
- Bevacizumab, Transarterial chemoembolisation (TACE)
- Where
- 3 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma Non-resectable
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05608200
- Testing
- Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
- Trial name
- NCT05320692
- Testing
- TACE+Camrelizumab+Apatinib mesylate, TACE
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.
- Trial name
- NCT04974281
- Testing
- PD-1 and Lenvatinib Plus TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Unresectable Hepatocellular Carcinoma
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
- Trial name
- NCT06593964
- Testing
- Thermosensitive Nanogel Embolic Agent
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
The purpose of this study is to determine whether neoadiuvant therapy with sorafenib increases the efficacy of thermal ablation in inducing the necrosis of hepatocellular carcinoma.
- Trial name
- LANEX (NCT01507064)
- Testing
- Sorafenib, laser ablation (LA)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Cardarelli Hospital
Carcinoma, Hepatocellular
Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
Primary Outcome Measures: To compare the progression free survival(PFS) in patients with unresectable hepatocellular carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without Huachansu, and the…
- Trial name
- NCT01715532
- Testing
- Huachansu, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Hepatocellular Carcinoma
Surefire Precision Infusion System Registry
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver…
- Trial name
- NCT02967523
- Testing
- DEB-TACE with Surefire Precision Infusion System
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- Surefire Medical, Inc.
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04592029
- Testing
- TACE combined with sintilimab and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Cancer, Transcatheter Arterial Chemoembolization
Effectiveness of Positioning on Back Pain After TACE Among Patients With HCC
Changing patients' position in the bed after TACE can decrease the level of back pain without increasing the amount of bleeding and hematoma,bring patients some comfort and relieving abdominal bloating, increase patients'…
- Trial name
- NCT03784469
- Testing
- Changing body position in bed
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion
Whether preoperative transarterial chemoembolization can prolong survival for the resectable hepatocellular carcinoma remains controversial, particularly in patients with portal vein tumor thrombi.
- Trial name
- NCT01952353
- Testing
- Preoprative TACE, Liver resection plus Thrombectomy
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sun Yat-sen University
Carcinoma. Hepatocellular
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis
The presence of portal vein tumor thrombosis (PVTT)in patients with HCC is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT01911000
- Testing
- RT and hyperthermia after TACE
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Samsung Medical Center